Lyme Disease and Papilledema: A Retrospective Study on Clinical Characteristics and Outcomes

J Child Neurol. 2024 Aug;39(9-10):334-342. doi: 10.1177/08830738241273376. Epub 2024 Sep 2.

Abstract

Objective: Describe the clinical characteristics, treatment strategies, and outcome data of children with papilledema associated with Lyme disease at a large tertiary care pediatric hospital.

Methods: Retrospective cohort study of children 1-18 years old who received care at our institution between 1995 and 2019 with concurrent diagnoses of papilledema and Lyme disease. Data were abstracted from records and prospective family surveys.

Results: Among 44 children included (median age 9.7 years), 66% (29/44) had additional cranial neuropathies, and 78% (32/41) had cerebrospinal fluid pleocytosis. All children were treated with antibiotics (39% oral, 55% intravenous, 7% both); 61% (27/44) were also treated with oral acetazolamide. Symptoms fully resolved in 86% (30/35) of children with follow-up data. Proportion recovered did not significantly differ by antibiotic administration route or presence/absence of cerebrospinal fluid pleocytosis.

Conclusions: Papilledema in Lyme disease may occur with or without cerebrospinal fluid pleocytosis. Most children recover without residual deficits following treatment, although exceptions exist.

Keywords: intracranial hypertension; neuroophthalmology; pediatric.

MeSH terms

  • Acetazolamide / therapeutic use
  • Adolescent
  • Anti-Bacterial Agents* / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Leukocytosis / cerebrospinal fluid
  • Leukocytosis / complications
  • Lyme Disease* / complications
  • Lyme Disease* / drug therapy
  • Male
  • Papilledema* / drug therapy
  • Papilledema* / etiology
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Acetazolamide